Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease.
The A-allele of the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with decreased enzymatic activity and higher dopamine availability. We studied 219 patients with PD who were free of dyskinesias at baseline and underwent thorough annual examinations. The A-allele of the COMT Val158Met polymorphism was related to an increased risk of developing dyskinesias during follow-up, in a dose-dependent manner (adjusted hazard ratios for the AG and AA genotypes [compared to GG]: 2.09 [95% confidence interval (CI), 1.07-4.06] and 2.81 [CI, 1.43-5.54], respectively). This finding suggests that genetic factors may affect susceptibility to dyskinesias in PD.